ADA advises doctor visit for Avandia users

June 11, 2007

In light of recently published data regarding the cardiovascular risks of rosiglitazone (Avandia, GlaxoSmithKline), the American Diabetes Association is strongly encouraging patients to consult their physician if they are currently taking the drug.

In light of recently published data regarding the cardiovascular risks of rosiglitazone (Avandia, GlaxoSmithKline), the American Diabetes Association is strongly encouraging patients to consult their physician if they are currently taking the drug. The group said that, although the interim analysis of the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) trial published in the June 5 issue of the New England Journal of Medicine did not have the statistical power to reach a definitive answer as to all of the cardiovascular risks that may be associated with the drug, the results did show an increased risk of heart failure. When these results are combined with other recently published data, a concern about the risk still exists, said ADA. The association reminds patients not to stop taking the drug without first talking to their healthcare provider.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.